Form 8-K

8-K — InMed Pharmaceuticals Inc.

Accession: 0001213900-26-048064

Filed: 2026-04-27

Period: 2026-04-21

CIK: 0001728328

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Material Modifications to Rights of Security Holders

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0287728-8k_inmed.htm (Primary)

EX-10.1 — SABBY PREFERRED INVESTMENT OPTION AMENDING AGREEMEN (ea028772801ex10-1.htm)

EX-10.2 — FORM OF WAINWRIGHT PREFERRED INVESTMENT OPTION AMENDING AGREEMENT (ea028772801ex10-2.htm)

EX-99.1 — PRESS RELEASE (ea028772801ex99-1.htm)

GRAPHIC (ea028772801_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0287728-8k_inmed.htm · Sequence: 1

false

0001728328

2026-04-21

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 21, 2026

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia

001-39685

98-1428279

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

InMed Pharmaceuticals Inc.

Suite 1445 - 885 W. Georgia Street,

Vancouver, B.C.

Canada

V6C 3E8

(Address of Principal Executive Offices)

(Zip Code)

Company’s telephone number, including

area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see

General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange

on which registered

Common Shares, no par value

INM

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive

Agreement.

Preferred Investment Option Amending Agreement

with Sabby Volatility Warrant Master Fund, Ltd.

As previously reported, pursuant to the terms

of the Preferred Investment Options dated October 26, 2023 and June 26, 2025 (together, the “Sabby Preferred Investment Options”

and each a “Sabby Preferred Investment Option”), InMed Pharmaceuticals Inc. (the “Company”) provided Sabby Volatility

Warrant Master Fund, Ltd. (“Sabby”) with the right to subscribe for and purchase from the Company, in the aggregate, up to

2,151,478 common shares in the capital of the Company at an exercise price per common share of $2.436, subject to adjustment (the “Sabby

Exercise Price”). The Sabby Preferred Investment Options were offered in private placements pursuant to Section 4(a)(2) of the Securities

Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder.

On April 21, 2026, the Company entered into a

Preferred Investment Option Amending Agreement (the “Sabby Preferred Investment Option Amending Agreement”) with Sabby to

amend the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.

The foregoing description of the Sabby Preferred

Investment Option Amending Agreement is not complete and is qualified in its entirety by the full text of the Sabby Preferred Investment

Option Amending Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K (this “Report”) and

incorporated herein by reference.

Preferred Investment Option Amending Agreement

with Affiliates of H.C. Wainwright & Co., LLC

As previously reported, pursuant to the terms of Preferred Investment Options dated November 21, 2022, October 26, 2023 and June 26, 2025

(together, the “Wainwright Preferred Investment Options” and each a “Wainwright Preferred Investment Option”),

the Company provided three affiliates of H.C. Wainwright & Co., LLC (“Wainwright” and, such affiliates of Wainwright,

the “Wainwright Parties” and each, a “Wainwright Party”) with the right to subscribe for and purchase from the

Company, in the aggregate, up to 153,236 common shares in the capital of the Company (on a post-consolidation basis) at an exercise price

per common share of $82.50, $20.75 and $3.2013 (in each case, on a post-consolidation basis), respectively, subject to adjustment in each

case (together, the “Wainwright Exercise Prices”). The Wainwright Preferred Investment Options were offered in private placements

pursuant to Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.

On April 24, 2026, the Company entered into Preferred Investment Option Amending Agreements (the “Wainwright Preferred Investment

Option Amending Agreements”) with each Wainwright Party to amend the Wainwright Exercise Prices contained in each Wainwright Preferred

Investment Option to $0.80.

The foregoing description of the Wainwright Preferred Investment Option Amending Agreements is not complete and is qualified in its entirety

by the full text of the Wainwright Preferred Investment Option Amending Agreements, a copy of a form of which is filed as Exhibit 10.2

to this Report and incorporated herein by reference. The Wainwright Preferred Investment Option Amending Agreements are identical to each

other except the names of the Wainwright Parties and the number of common shares that can be purchased by each Wainwright Party.

Item 3.03 Material Modification to Rights of

Security Holders.

To the extent required by Item 3.03 of Form 8-K,

the information contained in Item 1.01 of this Report is incorporated by reference herein.

Item 8.01 Other Events.

On April 27, 2026, the Company issued a press

release announcing the amendments to the Sabby Preferred Investment Options and the Wainwright Preferred Investment Options. A copy of

the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The press release contains forward-looking

statements and includes cautionary statements identifying important factors that could cause actual results to differ materially from

those in the forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

10.1

Sabby Preferred Investment Option Amending Agreement

10.2

Form of Wainwright Preferred Investment Option Amending Agreement

99.1

Press Release

104

Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INMED PHARMACEUTICALS INC.

Date: April 27, 2026

By:

/s/ Eric A Adams

Eric A Adams

President & CEO

EX-10.1 — SABBY PREFERRED INVESTMENT OPTION AMENDING AGREEMEN

EX-10.1

Filename: ea028772801ex10-1.htm · Sequence: 2

Exhibit

10.1

preferred investment

option AMENDING AGREEMENT

THIS PREFERRED INVESTMENT OPTION AMENDING

AGREEMENT (the “Agreement”) is dated April 21,

2026 between:

SABBY VOLATILITY WARRANT MASTER FUND, LTD.

(the “Holder”)

-and-

INMED PHARMACEUTICALS INC.

(the “Company”).

WHEREAS:

(A) pursuant to the terms of Preferred Investment Options dated October 26, 2023 and June 26, 2025 (together,

the “Preferred Investment Options”, and each, a “Preferred Investment Option”), the Company has

provided the Holder with the right to subscribe for and purchase from the Company, in the aggregate, up to 2,151,478 Common Shares in

the capital of the Company at an exercise price per Common Share of $2.436, subject to adjustment (the “Exercise Price”);

(B) the parties wish to amend the Exercise Price contained in each Preferred Investment Option, in each case

in accordance with Section 5. l) thereof; and

Investment Options.

NOW THEREFORE, in consideration of the

mutual covenants and agreements contained in this Agreement and other good and valuable consideration (the sufficiency and receipt of

which are hereby acknowledged), the Holder and the Company agree as follows:

1. Section 2. b) of each Preferred Investment Option is, without any further action on the part of any Person,

hereby amended by deleting “$2.436” and replacing it with “$0.80”.

2. For certainty, the parties hereto agree that, except as specifically provided herein, the terms and conditions

of each Preferred Investment Option are hereby confirmed and continue in full force and effect.

3. All questions concerning the construction, validity, enforcement and interpretation of this Agreement

shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles

of conflicts of law thereof.

4. This Agreement shall enure to the benefit of and be binding upon the parties hereto and their respective

legal representatives, heirs, executors, administrators, successors and assigns.

5. This Agreement may be executed in any number of separate counterparts and all such signed counterparts

will together constitute one and the same agreement. To evidence its execution of an original counterpart of this Agreement, a party may

send a copy of its signature on the execution page hereof to the other parties by facsimile or other means of recorded electronic transmission

(including in PDF form) and such transmission shall constitute valid delivery of an executed copy of this agreement to the receiving party.

[Remainder of page intentionally left blank;

signature page follows.]

The undersigned hereby agree to the terms set

forth herein as of the date first written above.

SABBY VOLATILITY WARRANT MASTER FUND, LTD.

Per:

Name:

Title:

INMED PHARMACEUTICALS INC.

Per:

Name:

Title:

[Signature Page

– Preferred Investment Option Amending Agreement]

EX-10.2 — FORM OF WAINWRIGHT PREFERRED INVESTMENT OPTION AMENDING AGREEMENT

EX-10.2

Filename: ea028772801ex10-2.htm · Sequence: 3

Exhibit 10.2

Form OF preferred

investment option AMENDING AGREEMENT

THIS PREFERRED INVESTMENT OPTION AMENDING

AGREEMENT (the “Agreement”) is dated April 24,

2026 between:

[ ]1

(the “Holder”)

-and-

INMED PHARMACEUTICALS INC.

(the “Company”).

WHEREAS:

(A) pursuant to the terms of Preferred Investment Options dated November

21, 2022, October 26, 2023, and June 26, 2025 (together, the “Preferred Investment Options”),

the Company has provided the Holder with the right to subscribe for and purchase from the Company, in

the aggregate, up to [ ]2 Common Shares (on a post-consolidation basis) in the capital of

the Company at exercise prices per Common Share of $3.30 (or $82.50 on a post-consolidation basis),

$1.03750 (or $20.75 on a post-consolidation basis), and $3.2013, respectively, subject to adjustment

in each case (the “Exercise Price”);

(B) the parties wish to amend the Exercise Price contained in each Preferred Investment Option, in each case

in accordance with Section 5. (l) thereof; and

Investment Option.

NOW THEREFORE, in consideration of the

mutual covenants and agreements contained in this Agreement and other good and valuable consideration (the sufficiency and receipt of

which are hereby acknowledged), the Holder and the Company agree as follows:

1. Section 2. (b) of each Preferred Investment Option is, without any further action on the part of any Person,

hereby deleted in its entirety and replaced with:

“b) Exercise Price.

The exercise price per share of Common Shares under this Preferred Investment Option shall be $0.80, subject to adjustment hereunder (the

“Exercise Price”).”

2. For certainty, the parties hereto agree that, except as specifically provided herein, the terms and conditions

of each Preferred Investment Option are hereby confirmed and continue in full force and effect.

3. All questions concerning the construction, validity, enforcement and interpretation of this Agreement

shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles

of conflicts of law thereof.

4. This Agreement shall enure to the benefit of and be binding upon the parties hereto and their respective

legal representatives, heirs, executors, administrators, successors and assigns.

5. This Agreement may be executed in any number of separate counterparts and all such signed counterparts

will together constitute one and the same agreement. To evidence its execution of an original counterpart of this Agreement, a party may

send a copy of its signature on the execution page hereof to the other parties by facsimile or other means of recorded electronic transmission

(including in PDF form) and such transmission shall constitute valid delivery of an executed copy of this agreement to the receiving party.

[Remainder of Page Intentionally Blank;

Signature Page Follows]

1 Each of the Wainright Preferred Investment Option Amending

Agreements are identical except the name of the Wainright Party and the number of shares that can be purchased.

2 Each of the Wainright Preferred Investment Option Amending

Agreements are identical except the name of the Wainright Party and the number of shares that can be purchased.

The undersigned hereby agree to the terms set

forth herein as of the date first written above.

[ ]

INMED PHARMACEUTICALS INC.

Per:

Name:

Title:

[Signature Page – Preferred Investment

Option Amending Agreement]

EX-99.1 — PRESS RELEASE

EX-99.1

Filename: ea028772801ex99-1.htm · Sequence: 4

Exhibit 99.1

NASDAQ: INM

Suite 1445-885 West Georgia St.

Vancouver, BC, Canada V6C 3E8

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

InMed Pharmaceuticals Amends Preferred Investment

Options

Vancouver, BC – April 27, 2026 – InMed

Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focused

on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that

it has entered into amending agreements in respect of preferred investment options previously entered into with each of Sabby Volatility

Warrant Master Fund, Ltd. (“Sabby”) and certain affiliates of H.C. Wainwright & Co., LLC (the “Wainwright

Parties”).

As previously reported:

· pursuant to the terms of the preferred investment

options dated October 26, 2023 and June 26, 2025 (together, the “Sabby Preferred Investment Options”), the Company

provided Sabby with the right to subscribe for and purchase from the Company, in the aggregate, up to 2,151,478 common shares in the capital

of the Company (on a post-consolidation basis) at an exercise price per common share of $2.436, subject to adjustment (the “Sabby

Exercise Price”); and

· pursuant to the terms of the preferred investment

options dated November 21, 2022, October 26, 2023 and June 26, 2025 issued to the Wainwright Parties (collectively, the “Wainwright

Preferred Investment Options”, and together with the Sabby Preferred Investment Options, the “Preferred Investment

Options”), the Company provided the Wainwright Parties with the right to subscribe for and purchase from the Company, in the

aggregate, up to 153,236 common shares in the capital of the Company (on a post-consolidation basis) at exercise prices per common share

of $82.50, $20.75 and $3.2013 (in each case, on a post-consolidation basis), respectively, subject to adjustment in each case (collectively,

the “Wainwright Exercise Prices”).

The Company has entered into: (i) an amending

agreement with Sabby in respect of the Sabby Preferred Investment Options to amend the Sabby Exercise Price to $0.80; and (ii) amending

agreements with the Wainwright Parties in respect of the Wainwright Preferred Investment Options to amend the Wainwright Exercise Prices

in the Wainwright Preferred Investment Options to $0.80.

Each of the Preferred Investment Options were

offered in private placements pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.

No assurance can be given that any of the Preferred Investment Options will be exercised.

For further information, please see the Company's

filings with the Securities and Exchange Commission, including the Company's Current Reports on Form 8-K filed with the Securities and

Exchange Commission from time to time.

About InMed

InMed Pharmaceuticals is a pharmaceutical company

focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists

of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica,

we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary,

small molecule drug analogs. For more information, visit www.inmedpharma.com.

Investor Contact:

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

ir@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking

information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning

of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to

a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the

exercise of the Preferred Investment Options prior to their expiration.

With respect to the forward-looking information

contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary

regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions

to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties

and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements

to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information

contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s

Annual Report on Form 10-K, InMed’s Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on

www.sec.gov.

All forward-looking information herein is qualified

in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information

or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,

events or developments, except as required by law.

GRAPHIC

Filename: ea028772801_ex99-1img1.jpg · Sequence: 5

Binary file (9690 bytes)

Download ea028772801_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

Apr. 21, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 21, 2026

Entity File Number

001-39685

Entity Registrant Name

INMED PHARMACEUTICALS INC.

Entity Central Index Key

0001728328

Entity Tax Identification Number

98-1428279

Entity Incorporation, State or Country Code

Entity Address, Address Line One

InMed Pharmaceuticals Inc.

Entity Address, Address Line Two

Suite 1445 - 885 W. Georgia Street

Entity Address, City or Town

Vancouver

Entity Address, State or Province

Entity Address, Country

Entity Address, Postal Zip Code

V6C 3E8

City Area Code

(604)

Local Phone Number

669-7207

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Shares, no par value

Trading Symbol

INM

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration